T1	Participants 75 102	recurrent gastric carcinoma
T2	Participants 232 247	cancer patients
T3	Participants 369 418	a group of patients with recurrent gastric cancer
T4	Participants 482 526	1) Intradermal group (ID Group), 42 patients
T5	Participants 570 616	2) Intramuscular group (IM Group), 40 patients
T6	Participants 662 701	3) Control group (C Group), 39 patients
